Citron Research Issues $100 Target Price on CMPS

Andrew Left’s Citron Research issued a research report today on Compass Pathways (CMPS) giving it a target price of $100 per share.

The report begins by saying, “Today marks the start of Mental Illness Awareness Week introduced by US Congress in 1990 in an effort to increase awareness of mental health issues. Never in the past 30 years has this been more important than NOW as depression levels have soared as much as over 3x during the pandemic. Medications to treat both depression and anxiety are prescribed at alarming rates, often as long-term treatments with little significant improvement in patient health overall.

With that as a backdrop, we introduce what we believe to be the most compelling IPO of the year whose significance to humanity has the potential to be a generational stock – COMPASS Pathways (CMPS).”

Download Citron Research’s full report on CMPS below:

Become a Member of Psychstocks for FREE

Holler Box